Drug Resistance 1: Antibodies and ADCs

• 2955 · PDF ADC耐药癌细胞系的系统性机制分析 Systematic mechanistic profiling of ADC-resistant cancer cell lines Tingting Yuan, Yanqiu Bai, Lehua Cheng, Yanan Xu, Wenzhang Chen, Yan Gao, Zhuo Wen, Qiangqiang Fan, Zhengang Peng
• 2956 · PDF 戈沙妥珠单抗在乳腺癌模型中治疗反应的决定因素 Determinants of sacituzumab govitecan therapeutic response in breast cancer models Carson J. Walker, Nina Dashti-Gibson, Julia E. Altman, Rachel K. Myrick, Emily K. Zboril, Oniya M. Smith, David C. Boyd, Bin Hu, Mikhail G. Dozmorov, Joshua C. Harrell
• 2957 · PDF 视黄酸通路调控NECTIN4表达并增强膀胱癌中NECTIN4导向的嵌合抗原受体（CAR）T细胞和抗体药物偶联物疗法 Retinoic acid pathway regulates NECTIN4 expression and enhances NECTIN4-directed chimeric antigen receptor (CAR) T and antibody-drug conjugate therapies in bladder cancer Tamilla Nechiporuk, Sha Zhu, Yuxin Yang, Shivani Saxena, Jun Zhu, Rosalie Nolley, Imene Boukhalfa Ep Hanafi, Rhea Master, Elizabeth Yip, Kevin Chang, William Dougherty, Terence Friedlander, Vadim S. Koshkin, David Quigley, Jonathan Chou, Carissa E. Chu
• 2958 · PDF P-糖蛋白（ABCB1）过表达赋予EV耐药类器官和PDX模型对抗体-药物偶联物Enfortumab vedotin的耐药性 P-glycoprotein (ABCB1) overexpression confers resistance to the antibody-drug conjugate Enfortumab vedotin in EV-resistant organoid and PDX models Emilie Decaup, Claire Béraud, Isabelle Bernard-Pierrot, Guerric Gilbert, Clémentine Krucker, Xavier Gamé, Philippe Lluel, Nadège Bidan
• 2959 · PDF 提高B7-H3靶向抗体-药物偶联物在TP53缺陷型前列腺癌中的疗效 Improving the efficacy of B7-H3 targeting antibody-drug conjugates in TP53-deficient prostate cancer Javier Leo, Di Zhao
• 2960 · PDF 利用整合的ADC平台克服获得性和内在性耐药 Overcoming acquired and intrinsic resistance with an integrated ADC platform Jie Wen, Hao Cheng, Cheng Zhang, Bingrui Han
• 2961 · PDF 开发ADC耐药肿瘤模型用于新一代抗癌疗法的疗效评估 Developing ADC-resistant tumor models for efficacy evaluation of next-generation anticancer therapies Jian Feng, Fuyin Zhao, Xinlong Dong, Aaron Li Hua, Chenpan Nie, Dorrith Verstegen, Caitlyn Hulsebosch, Wubin Qian, Sheng Guo, Jessie (Jingjing) Wang, Lenno Krenning, Marrit Putker, Ludovic Bourre, Peng Wang, Jun Zhou
• 2962 · PDF 由IL-17信号和ROR1上调驱动的HER2 ADC耐药：用BRY812和BR111克服DS-8201耐药 HER2 ADC resistance driven by IL-17 signaling and ROR1 upregulation: Overcoming DS-8201 resistance with BRY812 and BR111 Qianqian Tao, Qinqin Zhuang, Qizhe Wu, Lei Nie, Gang Chen, Haibin Wang, Jingtao Lu
• 2963 · PDF 新型体内JIMT-1 DS8201a耐药模型的构建与表征及其疗效评估 Development and characterization of a novel in vivo JIMT-1 DS8201a resistant model and its efficacy evaluation Qikuan Chen, Longyun Zhang, Ya Xu, Jingjing Zhang, Li Li, Greg Liang, Mingqi Shao, Fan Feng, Yinfei Yin
• 2964 · PDF 通过耐药建模鉴定抗体-药物偶联物的协同双有效载荷组合以克服耐药 Identification of synergistic dual payload combinations for antibody-drug conjugates to overcome resistance through resistance modeling Lili Chai, Yue Zhai, Yan Zhang, Ying Bi, Xue Yang, Zhengtai Li, Tiejun Bing
• 2965 · PDF 鉴定TROP2作为KRAS G12C抑制中的适应性耐药机制及其治疗靶向 Identification of TROP2 as an adaptive resistance mechanism in KRAS G12C inhibition and its therapeutic targeting Masahiro Kashima, Hidenori Kitai, Yukiko Yoshida, Yuriko Ishida, Yuma Sato, Daisuke Morinaga, Kosuke Tsuji, Shotaro Ito, Kanako C. Hatanaka, Takuma Kobayashi, Yoshiki Shinomiya, Teppei Konishi, Yutaka Hatanaka, Jun Sakakibara-Konishi, Satoshi Konno
• 2966 · PDF Zongertinib耐受细胞在Her2阳性NSCLC中增强了对Topo1抑制的敏感性 Zongertinib-tolerant cells enhanced sensitivity to Topo1 inhibition in Her2-positive NCSLC Kohei Maruyama, Ryohei Katayama
• 2967 · PDF 基于拓扑异构酶的治疗药物选择压力下TOP1变异体的演变 Evolution of TOP1 variants under selective pressure from topoisomerase-based therapeutics Tejaswini Reddy, Lei Kang, Hung Le, Senthil Damodaran, Kanwal Pratap Singh Raghav, Scott Kopetz, Jordi Rodon Ahnert, Ecaterina Elena Dumbrava, Timothy A. Yap, Stephen Williams, Mark J. Routbort, Keyur P. Patel, Funda Meric-Bernstam
• 2968 · PDF EGFR S442突变赋予cetuximab耐药，可通过trastuzumab-deruxtecan阻断ERBB2予以克服 EGFR S442 mutation confers cetuximab resistance that can be overcome by ERBB2 blockade by trastuzumab-deruxtecan Neeraj Joshi, Sarah J. Harmych, Hidenori Tanaka, Galina Bogatcheva, Marisol A. Ramirez, Ramona Graves-Deal, Claiborne W. Tydings, Claudia C. Wahoski, Chelsie K. Sievers, Maria Johnson Irudayam, James N. Higginbotham, Frank L. Revetta, Zhiguo Zhao, Jeffrey L. Franklin, Binyam Yilma, Tina M. O'Grady, Stamatina Fragkogianni, Metamia Ciampricotti, M Kay Washington, Xingyi Guo, Allison S. Walker, Jens Meiler, Qi Liu, Robert J. Coffey, Eben L. Rosenthal, Bhuminder Singh
• 2969 · PDF B836：一种作为临床候选药物用于克服trastuzumab deruxtecan耐药的新型双特异性抗体-药物偶联物(ADC) B836: A novel bispecific antibody-drug conjugate (ADC) as a clinical candidate to overcome trastuzumab deruxtecan resistance Yi Zhao, Huahua Hao, Xin Yang, Weiwei Pan, XinxinLiang, Quanai Zhang, Xiaoxia Liu, Jingting Cui, Elizabeth Wu, Zhican Qu
• 2970 · PDF HER3-DXd在结直肠癌PDX模型中疗效有限，揭示分子耐药机制并为合理联合策略提供依据 Limited efficacy of HER3-DXd in colorectal cancer PDX models reveals molecular resistance mechanisms and informs rational combinatorial strategies Preeti Kanikarla, Alexey Sorokin, Alisha Bent, Kelly Gale, Fengqin Gao, Zhensheng Liu, Kanwal Pratap Singh Raghav, Scott Kopetz
• 2971 · PDF 对获得性化疗耐药SCLC模型的深入分析揭示SLFN11依赖性的抗体-药物偶联物载荷敏感性及ATR抑制剂协同作用 In-depth profiling of SCLC models of acquired chemoresistance reveals SLFN11-dependent antibody-drug conjugate payload sensitivity and ATR inhibitor synergy Buesra Ernhofer, Lisa Glatt, Benjamin Morris, Beata Szeitz, Zsolt Megyesfalvi, Abigail Deloria, Diana Piesel, Laura Schnell, Kristiina Boettiger, Amirali Karimi, Monique Nilsson, Melinda Rezeli, Simon Heeke, John Victor Heymach, Clemens Aigner, Balazs Dome, Karin Schelch
• 2972 · PDF TROP2上调及其与HER2的相互作用介导trastuzumab耐药 TROP2 upregulation and interaction with HER2 mediate trastuzumab resistance Yuan-Liang Wang, Chi-Huan Lu, Cheng-Yen Wei, Jye-Yu Huang, Woan-Eng Chan, Lu-Tzu Chen, Ya-Chi Chen
• 2974 · PDF TROP2靶向抗体-药物偶联物(ADC)的抗癌效应可能因癌细胞中胆固醇代谢失调而减弱 The anticancer effect of TROP2-targeted antibody-drug conjugates (ADC) is potentially attenuated by dysregulated cholesterol metabolism in cancer cells Kimio Yonesaka, Yusuke Kawanaka, Takashi Kurosaki, Satomi Watanabe, Junko Tanizaki, Kazuko Sakai, Takeshi Teramura, Kazuto Nishio, Hidetoshi Hayashi
• 2975 · PDF Q702 增强曲妥珠单抗对 HER2+ 胃癌细胞的疗效 Q702 enhances trastuzumab efficacy for HER2 + gastric cancer cells Mi Young Kim, Yoonji Lee, Kiyean Nam, Jin-Soo Kim

在会议检索中浏览本分会场